International journal of chronic obstructive pulmonary disease · 2025
Observational and Genetic Evidence Reveals the Effect of Serum Lipid Levels on COPD Risk.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jia Guobing, Guo Tao, Liu Lei, He Chengshi
Аннотация
BACKGROUND: Disorders of lipid metabolism are linked to an increased risk of various diseases; however, their association with chronic obstructive pulmonary disease (COPD) remains unclear. This study aimed to examine the relationship between serum lipid levels and COPD risk.
METHODS: The methods of the National Health and Nutrition Examination Survey (NHANES) and Mendelian randomization (MR) analyses were employed to investigate the relationships between lipids and COPD across multiple populations. Data from 2013 to 2023 were selected for the NHANES study on US population, and weighted multivariable-adjusted logistic regression was employed as the primary statistical method. And data utilized for the MR analysis were derived from genome-wide association studies (GWAS) conducted on European and East Asian populations, with inverse-variance weighted (IVW) method serving as the principal statistical approach.
RESULTS: The NHANES analyses indicated that higher levels of total cholesterol (TC) (OR = 0.85, 95% CI = 0.77-0.93), non-high-density lipoprotein cholesterol (non-HDL-C) (OR = 0.86, 95% CI = 0.78-0.94) and low-density lipoprotein cholesterol (LDL-C) (OR = 0.85, 95% CI = 0.74-0.97) were associated with a reduced risk of COPD in the US population. In the MR analyses, TC (OR = 0.90, 95% CI = 0.84-0.95), non-HDL-C (OR = 0.91, 95% CI = 0.85-0.96), and LDL-C (OR = 0.88, 95% CI = 0.82-0.94) were causally linked to a decreased risk of COPD in the European population. Similar associations were observed in the East Asian population.
CONCLUSION: Our study identified associations between TC, non-HDL-C, and LDL-C with a reduced risk of COPD. This underscores the importance of monitoring lipid metabolism in patients with COPD and provides supporting evidence for the use of lipid-based therapies in its treatment.
METHODS: The methods of the National Health and Nutrition Examination Survey (NHANES) and Mendelian randomization (MR) analyses were employed to investigate the relationships between lipids and COPD across multiple populations. Data from 2013 to 2023 were selected for the NHANES study on US population, and weighted multivariable-adjusted logistic regression was employed as the primary statistical method. And data utilized for the MR analysis were derived from genome-wide association studies (GWAS) conducted on European and East Asian populations, with inverse-variance weighted (IVW) method serving as the principal statistical approach.
RESULTS: The NHANES analyses indicated that higher levels of total cholesterol (TC) (OR = 0.85, 95% CI = 0.77-0.93), non-high-density lipoprotein cholesterol (non-HDL-C) (OR = 0.86, 95% CI = 0.78-0.94) and low-density lipoprotein cholesterol (LDL-C) (OR = 0.85, 95% CI = 0.74-0.97) were associated with a reduced risk of COPD in the US population. In the MR analyses, TC (OR = 0.90, 95% CI = 0.84-0.95), non-HDL-C (OR = 0.91, 95% CI = 0.85-0.96), and LDL-C (OR = 0.88, 95% CI = 0.82-0.94) were causally linked to a decreased risk of COPD in the European population. Similar associations were observed in the East Asian population.
CONCLUSION: Our study identified associations between TC, non-HDL-C, and LDL-C with a reduced risk of COPD. This underscores the importance of monitoring lipid metabolism in patients with COPD and provides supporting evidence for the use of lipid-based therapies in its treatment.